[According to Tonghuashun] Qi Zheng Tibetan Medicine’s Lei Jufang submits a proposal to the Two Sessions: Improve the evaluation system for traditional Chinese medicine research.

　　In this year’s Two Sessions, Lei Jufang, a member of the National Committee of the Chinese People's Political Consultative Conference and Chairperson of Tibet Qizheng Tibetan Medicine Co., Ltd. (002287), submitted proposals focusing on establishing Tibetan medicine resource conservation areas, strengthening the development of Tibetan medicine quality standards, and improving the evaluation system for traditional Chinese medicine research.

　　According to Tonghuashun (300033) Finance, Qizheng Tibetan Medicine is a Tibetan medicine manufacturer primarily engaged in the research and development, production, and sales of innovative Tibetan medicines. As a member of the National Committee of the Chinese People's Political Consultative Conference for two consecutive terms, Lei Jufang, Chairperson of Qizheng Tibetan Medicine, has submitted dozens of proposals on issues related to ethnic medicine to the CPPCC over the years.

　　This year, Lei Jufang, in her proposal "On Establishing a Tibetan Medicine Resource Conservation Zone," pointed out that Tibet boasts 2,436 species of Tibetan medicinal resources, including 2,172 plant species, 214 animal species, and 50 mineral species. However, due to factors such as technological limitations and market conditions, these resource advantages have not been fully exploited. She recommends establishing a Tibetan medicine resource conservation zone centered on Tibet and including it in the national “13th Five-Year Plan” major project database for the protection and development of Chinese medicinal materials.

　　The specific measures include the implementation of four major projects: First, the Wild Tibetan Medicinal Herb Conservation Project, which involves establishing a Tibetan medicinal herb resource exhibition area and a germplasm bank to collect, conserve, and propagate Tibetan medicinal herb resources. It will also carry out ex situ conservation efforts and set up a germplasm and gene bank for Tibetan medicinal herbs. Second, the High-Quality Tibetan Medicinal Herb Production Base Project, aimed at creating demonstration bases for Tibetan medicinal herb cultivation characterized by “large-scale planting, standardized production, branded products, and industrialized management.” Third, the Tibetan Medicine Cultural Preservation Project, which involves setting up exhibition centers at Tibetan medicine research bases such as Zagon Gou in Nanyi Gou, Milin County, and restoring and recreating certain aspects of Tibetan medicine teaching and research. Fourth, the Tibetan Medicine Innovation Project, which focuses on developing technologies for the propagation of Tibetan medicinal herb seedlings and on the development of new products—including Tibetan medicinal drugs, health supplements, cosmetics, and novel food resources—to promote the comprehensive utilization of Tibetan medicinal herb resources.

　　Meanwhile, Lei Jufang also put forward suggestions for strengthening the development of quality standards for Tibetan medicine. She believes that current Tibetan medicine standards still face significant challenges, which severely hinder the modernization of Tibetan medicine and the growth of its industry. She recommends accelerating the development of “two standards and one specification”—namely, standards for raw medicinal materials, standards for finished Tibetan medicines, and specifications for the processing of medicinal herbs.

　　In addition, Lei Jufang’s proposal also addresses issues such as revising the dosage and administration standards for Chinese medicinal materials classified as toxic in the National Pharmacopoeia, the challenge of conducting multi-indication clinical trials during the formulation transformation of ethnic medicines, ensuring that the roles of traditional Chinese medicine and ethnic medicines are appropriately reflected in clinical pathways, scientifically expanding the catalog of substances that serve both as medicine and food, and improving the evaluation system for TCM research.

　　Regarding the improvement of the scientific research evaluation system for traditional Chinese medicine (TCM), she mentioned in her proposal that the outlook for proprietary Chinese medicines is currently not optimistic, with growth significantly slowing down and falling below the overall growth rate of the pharmaceutical industry. She also pointed out that in most of the pilot cities undergoing healthcare reform nationwide, the elimination of proprietary Chinese medicines from the catalog can only be achieved through volume-based procurement (secondary price negotiations) and by assessing whether the products meet the criteria for price reductions. She believes that this approach is extremely detrimental to the development of TCM.

　　In this regard, Lei Jufang suggests abolishing the practice of phasing out traditional Chinese medicines (TCMs) through volume-based procurement in pilot cities. Instead, she recommends establishing a provincial-level mechanism for clinical expert review of the TCM catalog, maintaining the 15% hospital markup on TCMs, and providing support for the development of the TCM industry. Furthermore, she calls for advancing and improving the research evaluation system for TCM, establishing and refining research evaluation standards and systems that are tailored to the unique characteristics of TCM, and studying and perfecting incentive policies that promote innovation in TCM.

　　Reporting media: Tonghuashun Finance

　　Report link: http://yuanchuang.10jqka.com.cn/20160304/c588316178.shtml